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Solute, amino acid, and hormone changes with coated charcoal
hemoperfusion in uremia. This investigation assesses the effect of
two-hour activated charcoal hemoperfusion using a column con-
taining 300 g of acrylic hydrogel-coated activated charcoal either
alone or combined with hemodialysis on small and "middle mole-
cule" removal in uremic patients. Comparison was made with
standard five-hour hemodialysis. Two patients with dialysis en-
cephalopathy were treated with four-hour combined hemoperfu-
sionlhemodialysis without beneficial clinical effects. Hemoperfu-
sion increased the clearance rates of creatinine and urate when
combined with dialysis. Hemoperfusion alone removed 1.3 0.6 g
(mean SD) of creatinine and 0.6 0.2 g of urate, while combined
hemoperfusion/hemodialysis removed 1.7 0.6 g of creatinine and
1.0 0.5 g of urate in a two-hour period. Both treatment schedules
removed less solute than standard five-hour hemodialysis but were
associated with comparable "middle molecule" removal. Hemo-
perfusion accounted for additional amino acid removal when com-
bined with hemodialysis, while hemoperfusion alone produced
significant reduction only in the amino acid cystine. Changes in the
hormones thyroxine, triiodothyronine, human growth hormone,
and insulin were noted during the procedures. Acceptable falls in
platelet counts and fibrinogen occurred with hemoperfusion.
Coated charcoal hemoperfusion may prove to have a role in the
management of uremic patients, although the acrylic hydrogel-
coated charcoal hemoperfusion device requires modification to
increase efficiency and it requires combination with techniques
allowing fluid and electrolyte removal.
Modifications des substances dissoutes, des acides aminés et des
hormones par l'hémoperfusion sur charbon au cours de l'urémie.
Cette étude évalue les effets d'une hémoperfusion de deux heures,
sur charbon active, utilisant une colonne de 300 g de charbon
active recouvert d'hydrogel d'acrylique, seule ou combinée a une
hemodialyse, sur La soustraction de petites et moyennes molecules
a des malades urdmiques. La comparaison a été faite avec
l'hémodialyse habituelle de cinq heures. Deux malades atteints
d'encéphalopathie de La dialyse ont été traités par quatre heures
d'hémoperfusion et d'hémodialyse sans bénéfice clinique.
L'hémoperfusion augmente les clearances de Ia créatinine et de
l'acide urique quand elle est associée a l'hémodialyse.
L'hemoperfusion seule soustrait 1,3 0,6 g (mean so) de
créatinine et 0,6 0,2 g d'acide unque alors que l'association a
l'hémodialyse permet de soustraire 1,7 0,6 g de créatinine et 1,0
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0,5 g d'acide urique en deux heures. Les deux types de traite-
ment soustraient moms de substances dissoutes qu'une hémodia-
lyse de cinq heures mais réalisent une soustraction comparable de
moyennes molecules. L'hdmoperfusion determine une soustrac-
tion supplémentaire d'acides aminés quand elle est associée a
l'hemodialyse alors que l'hCmoperfusion seule ne produit de dimi-
nution significative que de la cystine. Des modifications des hor-
mones T4, T3, HGH et insuline ont été observées. Des chutes
acceptables des plaquettes et de fibnnogene sont survenues au
cours de l'hemoperfusion. L'hemoperfusion sur charbon enrobe
pourrait avoir une place dans le traitement des malades urémiques
encore que le système du charbon revétu d'un hydrogel acrylique
nécessite d'être modiflé pour augmenter son efficacité et d'être
associé a des techniques permettant Ia soustraction d'eau et
electrolytes.
Intermittent hemodialysis has evolved as the main-
stay of therapy for patients with end-stage chronic
renal failure. While technical innovations or im-
provements in dialysis apparatus have simplified the
technique and allowed its application to increasing
numbers of patients, it has become apparent that
prolonged intermittent and apparently adequate
hemodialysis does not completely reverse the meta-
bolic and endocrine consequences of uremia. The
metabolic and endocrine abnormalities which persist
despite hemodialysis influence the significant mor-
bidity and mortality which attend regular hemodialy-
sis therapy, lii, 2]. As a result, research in various
centers has been directed towards alternatives to
dialysis, adjuncts to dialysis, and improvement in
dialytic techniques.
In 1964, Yatzidis [3] proposed the use of hemoper-
fusion of blood directly over uncoated activated
charcoal particles for the treatment of uremia. He
demonstrated that charcoal hemoperfusion would re-
move urea, creatinine, uric acid, indican, phenols,
guanidine compounds, and organic acids, and he
suggested that two to three hours of treatment with
charcoal hemoperfusion was equivalent in terms of
solute removal to four to six hours of hemodialysis
with a Kolif twin-coil kidney. Subsequently, Chang
et al [41 observed that two hours of hemoperfusion
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through albumin-collodion-coated activated charcoal
was similar to six hours of standard hemodialysis in
maintaining patients symptom-free.
Early hemoperfusion devices utilized uncoated
and poorly washed charcoal granules, which in ani-
mals and man was associated with profound platelet
depletion and embolization of small charcoal parti-
cles [5, 61. Coating of charcoal granules with suitable
polymers has almost abolished particle embolization
and improved the hematologic side effects of hemo-
perfusion, Accordingly, in this study, a hemoperfu-
sion device containing acrylic hydrogel-coated acti-
vated charcoal was used.
This paper compares the effect of hemodialysis
with the effects of hemoperfusion alone or in combi-
nation with hemodialysis on solute, amino acid, and
hormone changes in uremic patients. Additionally,
the effects of hemoperfusion on coagulation status
were studied.
Methods
All patients, or next of kin where appropriate,
consented to this study. In a previous study [7],
three regularly dialyzed patients, stabilized on a five-
hour, three times per week, hemodialysis regimen,
were studied during six standard five-hour hemodia-
lyses and during six separate two-hour periods of
combined hemodialysis and charcoal hemoperfu-
sion. Hemodialysis was continued for three hours
after the two-hour combined treatment was discon-
tinued. The data derived from the standard dialysis
regimen or the two-hour combined dialysis and
hemoperfusion regimen gave base line data for direct
comparison with data derived from study of hemo-
perfusion alone. Seven patients were treated with a
two-hour period of hemoperfusion alone.
Two other patients with the syndrome of dialysis
encephalopathy [81 were treated with charcoal
hemoperfusion in series with hemodialysis for periods
of four hours in an attempt to delay the progression of
neurological deterioration; four treatments in one
patient and two treatments in the other were applied
without changing the hemoperfusion device
throughout.
In all patients, the activated charcoal column used
contained 300 g of acrylic hydrogel-coated (2% by
weight) activated charcoal (Smith and Nephew Re-
search, Ltd., Essex, England), which was used alone
or in combination with Travenol Ultraflo 145 or Cor-
dis Dow IV capillary dialyzers in the stable uremic
subjects, or combined with Travenol UF II or Dasco
SP67 dialyzers in the dialysis encephalopathy sub-
jects. Blood flow rates measured by air bubble transit
time were maintained at 300 mI/mm except in the
dialysis encephalopathy subjects when blood flow
rate was 150 to 200 mI/mm; dialysate flow rates
varied between 200 and 470 mI/mm, and dialysate
temperature was 37°C.
Two patients each had three combined hemoperfu-
sion/hemodialysis periods with the charcoal column
situated proximal to the dialyzer, but all other com-
bined treatments were carried out with the charcoal
column sited distal to the dialyzers.
Heparin sulfate was used as anticoagulant to main-
tain a whole-blood clotting time of 30 to 40 mm.
Where possible, protamine sulfate (100 to 200 mg)
was used at the cessation of treatment periods, to
reverse the action of heparin in order to determine
the effect of these treatments on coagulation tests
and coagulation factors.
Plasma solute clearance was calculated from the
formula:
Solute clearance (mi/mm) =
inlet solute cone. — outlet solute conc.blood flow rate x inlet solute cone.
Clearance data for urea, creatinine, urate, and phos-
phate were determined at timed intervals, and total
solute removal during each procedure was estimated
from calculation of the area between inlet-outlet con-
centration vs. time curve [91. Calculated solute re-
moval agreed well with determined solute removal (r
= 0.92, P < 0.001) in dialysate, as previously re-
ported [71.
Substances in the "middle molecular" weight
range (300 to 1500 daltons) were estimated before
and after each procedure with Sephadex G25 chro-
matography [10]. Percent fall in "middle molecule"
concentrations during each procedure was calculated
from measurement of area under the elution chroma-
tographs before and after each procedure. "Middle
molecule" clearance across the charcoal devices or
dialyzer was not calculated. Platelet and leukocyte
numbers were determined before, during, and after
each procedure, and coagulation tests (prothrombin
time, partial thromboplastin time, kaolin-cephalin
clotting time, and thrombin time) and assay of fibrin-
ogen, and coagulation factors II, V, VII to XII were
performed (only after heparin neutralization) before
and after treatment periods (hemodialysis N = 12,
hemoperfusion/hemodialysis N = 15, hemoperfusion
N = 4). In four subjects, screen filtration pressure
(SFP), by a modification of the method of Swank
Roth, and Jansen [11], was measured before and
after single hemoperfusion and 15 mm after starting
hemoperfusion at the inlet and the outlet of the char-
coal column. For comparison, SFP measurements
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were also taken at similar time intervals in six pa-
tients who were not in this study but who were
undergoing routine hemodialysis.
The free-plasma amino acids, alanine, cystine, gly-
cine, histidine, isoleucine, leucine, lysine, methio-
nine, phenylalanine, serine, threonine, tyrosine, and
valine, were measured by the method of Moore,
Spackman, and Stein [121 with modifications by
Perry and Hanson [13]. Free amino acids were deter-
mined before and after hemodialysis (N = 6), or
combined hemodialysis/hemoperfusion (N = 6), or
hemoperfusion alone (N = 6).
Radioimmunoassay of plasma for total triiodothy-
ronine (T3) and total thyroxine (T4) [141, insulin
[15], and human growth hormone (HGH) [16] were
measured before and after the procedures as well as
15 mm after starting the procedure at the inlet and
outlet of each circuit. Estimations of hormones were
made during standard hemodialysis (N = 12), during
combined hemodialysis/hemoperfusion (N = 12),
and during single hemoperfusion (N = 6).
Clinical observations on blood pressure were
made continuously during each procedure. Statisti-
cal analysis of all investigations were made using
Student's t test for paired data.
Results
No significant phosphate or urea removal was ob-
tained with hemoperfusion alone, and no additional
phosphate or urea removal occurred during com-
bined hemodialysis/hemoperfusion. No differences
were observed in clearance values when the charcoal
hemoperfusion device was placed before or after the
dialyzer, and for clarity the results were combined.
The mean SD creatinine and urate clearances for
all procedures are shown in Table 1. During com-
bined hemoperfusion/hemodialysis, creatinine and
urate clearance were respectively 100% and 50%
greater (P < 0.001) than hemodialysis alone. Creati-
nine clearance at 15 mm was significantly greater
with hemoperfusion alone (P < 0.05) than with stan-
dard hemodialysis, but no other significant differ-
ences in clearance were observed.
Calculated mean SD total solute removal for
procedures undertaken at 300 mI/mm blood flow are
shown in Table 2. There was a strong correlation
between the initial plasma creatinine value (6.6
[SD] 3.6 mg/100 ml) and total creatinine removed (1.3
[SD] 0.6 g/2 hr) during hemoperfusion alone (r =
0.95, N = 6, P <0.01). Table 2 also shows that total
solute removal (creatinine and urate) in a two-hour
combined hemoperfusion/hemodialysis period was
less than that achieved with a standard five-hour
hemodialysis (P <0.001).
Table 3 shows total solute removal (creatinine and
urate) achieved with four hours of combined hemo-
perfusion/hemodialysis in the patients with dialysis
encephalopathy. Total solute removal in these pa-
tients exceeded that achieved with five hours of
standard hemodialysis, although 'middle molecule"
reduction was not greater than with two hours of
combined therapy in the nonencephalopathic pa-
tients.
Table 4 shows the changes in plasma hormone
concentrations during the dialytic procedures. HGH
fell significantly (P < 0.05) over the time period of all
procedures, whereas total T4 rose with hemodialysis
alone, fell with combined hemodialysis/hemoperfu-
sion, and remained stable with hemoperfusion alone.
T4 appeared to be reduced over the charcoal column.
T3 levels fell only with hemoperfusion alone, al-
though there were significant variations in plasma
concentrations during each of the three different pro-
cedures. Plasma insulin levels were significantly re-
duced with hemoperfusion alone, although variations
in plasma insulin were noted during each procedure.
Table 5 shows the mean SD changes in free
amino acid concentrations occurring with each pro-
cedure, and Figure 1 shows the percentage change in
amino acids occurring during the procedures. Hemo-
dialysis alone was associated with significant
changes in alanine, cystine, glycine, histidine, threo-
nine, and valine, whereas hemoperfusion alone was
associated with a significant reduction in concentra-
tion of cystine and a rise in serine concentration.
Chromatograms of plasma eluted from Sephadex-
G25 read at 254 flM showed that all procedures re-
duced peaks occurring at a mol wt of 500 to 1,500
daltons (Table 6). Addition of hemoperfusion to
hemodialysis resulted in a greater mean percent fall
in "middle molecules" than hemodialysis alone, al-
though the changes failed to reach statistical signifi-
cance (P > 0.05). On the other hand, two hours of
hemoperfusion alone caused a reduction in "middle
molecule" concentrations equal to that of five hours
of standard hemodialysis (P > 0.05). Hemoperfusion
did not reduce "rebounds" in "middle molecule"
concentrations between treatments.
During all procedures, leukopenia occurred after
15 mm, but white blood cell count returned to normal
at the end of each procedure.
Platelet concentrations were reduced with hemo-
perfusion/hemodialysis (30 21%) and with hemo-
perfusion alone (18.8 21%) but not with hemodial-
ysis alone. Platelet counts reached their lowest
values after 15 mm of treatment with all treatment
procedures, and rose progressively thereafter. No
significant changes occurred in screen filtration pres-
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Table 1. Creatinine and urate clearances with dialysis and hemoperfusiona
Procedure
Creatinine clearance, mi/mm Urate clearance, mi/mm
15 mm 2 hr15 mm 2 hr
Standard hemodialysis (N = 18) 114 59 113 46 107 29 105 52
2-hr hemodialysis/
hemoperfusion (N = 18) 275 38b 227 44b 165 43b 144 76°
2-hr hemoperfiision(N = 6) 181 7b 123 14 116±29 71 17
N = single estimation during each procedure. Blood flow rate QB = 300 mI/mm; dialysate flow rate QD = 200 to 470
mi/mm; and dialysate temperature = 37°C.
II Compared with corresponding standard hemodialysis period, P <0.001.
Compared with corresponding standard hemodialysis period, P <0.05.
Table 2. Total creatinine and urate removal with dialysis and hemoperfusiona
Procedure
Creatinine, g Urate, g
2 hr 5 hr 2 hr 5 hr
Standard hemodialysis (N = 18) 1.6 0.4 3.1 1.3 0.7 0.3 1.6 0.5
2-hr hemodialysis!
hemoperfusion (N = 18) 1.7 0.6l — 1.0 0.5 —
Hemodialysis component 1.0 0.6 — 0.5 0.2 —
Hemoperfusion component 0.8 0.2 — 0.4 0.3 —
2-hr hemoperfusion (N = 6) 1.3 0•6b — 0.6 02b
a QB = 300 mI/mm; QD = 200 to 470 mi/mm; and dialysate temperature = 37°C.
b Significantly less than 5-hr standard hemodialysis (P < 0.05).
Table 3. Totai creatinine and urate removal with combined hemodialysis/hemoperfusion in two dialysis encephalopathy
patients
Creatinine, g Urate, g
Procedure 2 hr 4 hr 2 hr 4 hr
4-hr hemodialysis!
hemoperfusion (N = 6) 1.8 0.3 3.3 0.4 1.2 0.4 2.4 0.8
Hemodialysis component 1.1 0.1 1.9 0.3 0.8 0.2 1.6 0.5
Hemoperfusion component 0.8 0.2 1.3 0.3 0.4 0.1 0.8 0.3
a QB = 150 to 200 mI/mm; Q = 400 ml/min; dialysate temperature = 37°C.
Table 4. Changes in hormones with dialysis and hemopeifusion
Hormone Start 15-mm inlet1 (A1) 15 mm-inlet2 (A2) 15 mm outlet (V) End
5-hr hemodialysis (N = 12)
T3, nmoie/liter 1.1 0.3 0.9 0.2 — 1.0 0.5 1.4 Ø3)
T4, nmole/liter 68.0 12.3 57.1 20. — 64.3 8.0 76.4 9•7b
Insulin, mU/liter 23.7 15.4 16.6 12.7° — 18.7 13.Oa 31.1 20.4
HGH, g/Iiter 28.9 30.3 34.1 29.9 — 41.2 35.1 3.7 42b
5-hr hemodialysis/hemoperfusion (N 12)
T3, nmole/iiter 1.2 0.3 0.7 0.3° 0.8 0.3° 0.7 0.3'° 1.1 0.5
T4, nmole/iiter 65.0 10.5 58.0 10•9b 55.1 17.7° 53.2 17.7° 57.8
Insulin, mU/liter 21.3 15.1 11.2 52b 12.3 4. 11.2 3.7° 28.0 15.0
HGH, pg/liter 44.3 29.6 53.6 25.5 42.7 21.6 52.8 34.6 5.9 67b
2-hr hemoperfusion (N = 6)
T3, nmoleiiter 1.1 0.4 0.8 0.2 — 0.7 0.3k 0.7 0.2k
T4, nmole/liter 75.7 12.8 63.4 9.8° — 66.2 12.0 75.2 7.1
Insulin, mUiiter 30.4 14.9 17.0 2.1 — 14.9 3.2 15.3 3.1°
HGH, pg/liter 9.4 3.4 11.2 3.9 — 11.0 4.2 4.4 3.8a
a p <0.05, compared with "start" value.
P < 0.01, compared with "start" value.
P <0.01, comparing A1 with V.
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Table 5. Plasma free amino acids, unoleIliter (mean SD)
Hemodialysi s alone (N 6) Hemodialysis/hemoperfusion Hemoperfusion alone (N = 6)
Amino acid Pre Post Pre Post Pre Post
Alanine 398.5 90.2 239.8 793a 394.5 50.9 265.3 89.la 269.8 37.5 251.0 20.1
Cystine 192.3 37.9 106.8 32.6a 157.2 22.0 77.5 l9.4 158.9 19.7 137.9 15.2a
Glycine 339.3 36.8 230.0 86.7a 323.5 60.4 246.0 35.l 318.3 64.7 297.5 50.0
Histidine 137.5 10.6 114.5 25.5 129.5 16.2 93.3 9.3 — —
Isoleucine 34.8 14.0 33.8 12.7 36.5 7.9 45.7 12.6 48.3 8.0 54.7 7.7
Leucine 67.0 16.4 72.8 28.8 72.7 13.5 89.0 23.5 69.4 9.5 91.3 11.5
Lysine 135.0 36.8 106.8 40.6 126.0 25.4 127.2 23.8 132.4 15.5 135.6 19.2
Methionine 24.7 4.0 19.3 35 24.2 4.2 21.3 4.3 26.7 3.9 25.0 2.3
Phenylalanine 56.7 8.1 51.8 13.4 58.3 3.8 52.6 6.6 57.9 5.8 62.3 6.1
Serine 62.0 7.8 51.3 13.1 58.2 12.0 52.8 10.0 73.0 12.9 100.3 8.6a
Threonine 90.7 16.2 72.0 15.2 89.7 11.8 70.2 123b 88.4 10.1 98.5 10.7
Tyrosine 25.8 5.9 31.3 25.6 30.5 17.7 24.0 6.5 32.0 11.9 32.0 8.6
Valine 127.5 32.0 122.0 39.1 1515 16.5 116.0 379 148.8 23.8 168.6 22.5
Significantly dilTerent from prevalue (P < 0.05).
Significantly different from prevalue (P < 0.025).
sure (SFP) measurements with hemodialysis alone
(28.5 11.7 mm Hg predialysis and 38.5 16.9 mm
Hg postdialysis, P > 0.05, N = 6), or with hemoper-
fusion alone (31 11.8 mm Hg predialysis, 44.8
5.1 mm Hg postdialysis, P > 0.05, N = 4). No
significant differences in SFP values were observed
15 mm after starting dialysis or hemoperfusion in
blood taken from the inlet and outlet ports of the
apparatus. No changes occurred in coagulation tests
or coagulation factors II to XII with any of the
procedures, although fibrinogen was reduced with
combined hemoperfusionlhemodialysis (10%, P <
0.05) or hemoperfusion alone (30%, P < 0.01).
Clinical complications of hemoperfusion were
minimal. Hypotension occurred on two occasions
when the hemoperfusion device was combined with
a large volume dialyzer (Travenol Ultraflo 145), and
no hemorrhagic complications occurred. In the very
short time of treatment, clinical response to repeated
hemoperfusion in the patients with dialysis encepha-
lopathy was not apparent and both eventually died as
a result of deterioration in their neurological status.
Discussion
Chang et al [4] have reported that two hours of
albumin-collodion-coated charcoal hemoperfusion
alone or used alternately with hemodialysis can
Standard
dialysis
Dialysis and
hemoperfusion
Hemoperfusion
alone
35.0 20.1% 42.7 19.4%a 45.1 22.6%a
N=14 N=12 N=6
Comparison with standard hemodialysis, P > 0.05.
Standard 5-hr hemodialysis (N = 4)
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Fig. 1. Percent changes in amino acids with dialysis, combined
dialysis/hemoperfusion, and hemoperfusion alone. One asterisk
(*) denotes P < 0.05; two asterisks (**) denote P < 0.025.
Table 6. Percentage 'middle molecule" reduction with
hemodialysis and hemoperfusion (mean SD)
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maintain uremic patients symptom-free for pro-
longed periods. For repeated use, however, Chang
[171 and others [71 have shown that hemoperfusion
requires combination with hemodialyzer or ultrafil-
trator to effect fluid, electrolyte, and urea removal.
This study has shown that charcoal hemoperfusion
can increase efficiency of hemodialysis, during com-
bination therapy, but that small molecule removal
during two-hour periods of acrylic hydrogel-coated
charcoal hemoperfusion alone or combined with
hemodialysis is significantly less than that of five-
hour standard hemodialysis.
On the other hand, middle molecule" reduction
was greater with hemoperfusion, a finding confirming
the earlier observations of Chang et al [18]. Re-
cently, Oules et al [19], using sophisticated analyti-
cal techniques [20], have demonstrated that three-
hour charcoal hemoperfusion with the Gambro Ad-
sorba 300 C hemoperfusion device quantitatively re-
duces the "middle molecule" peaks 7a, b, c, and d in
magnitude similar to that with four hours of standard
(cuprophan membrane) or high porosity (polyacrylo-
nitrile membrane) hemodialysis.
Although quantitative solute removal with com-
bined hemoperfusion/hemodialysis in this study was
less than that with standard hemodialysis, the quan-
tities removed concurred with those reported by
Chang et al [21] using combined albumin-collodion-
coated charcoal hemoperfusion/hemodialysis. The
quantities of small molecules removed in addition to
"middle molecular" weight substance removal may
be sufficient for long-term maintenance of uremic
patients, in view of the reported improvements in
peripheral neuropathy and maintenance of steady-
state achieved with repetitive hemoperfusionlhemo-
dialysis/ultrafiltration [291. As expected, extension
of the combined hemoperfusionlhemodialysis period
to four hours in the two encephalopathic patients
increased total small molecule removal, although this
was associated with saturation of charcoal for creati-
nine and urate adsorption and was not associated
with increase in "middle molecule" removal.
The effect of hemodialysis on thyroid hormones
has been previously studied; no significant differ-
ences across the dialyzer or before and after dialysis
have been observed for total T4, T3, and TSH [22,
231. Postdialysis levels of free T4, however, are
usually higher than predialysis levels because of hep-
arm-induced decreased binding of thyroxine to thy-
roglobulin [24, 25]. On the other band, acrylic-hy-
drogel-coated charcoal hemoperfusion has been
shown to remove free T3 and free T4 in patients with
thyroid storm [26]. Moreover, Burman et al [271,
using another sorbent, XAD-4 resin (an uncharged
amberlite resin) hemoperfusion in animals intoxi-
cated with T4 or T3, showed that total T4 and total
T3 as well as free T4 were removed at appreciable
rates over a two-hour hemoperfusion period. Varia-
tions in total T4 (normal range, 55 to 144 nmoles/
liter) and T3 (normal range, 0.9 to 2.8 nmoles/liter)
levels that are seen with the use of charcoal hemo-
perfusion in our patients could be accounted for by
the removal of total or the free component of T3 and
T4, although significant extraction of total T4 was
only observed across the hemodialysis/hemoperfu-
sion apparatus during combined treatment.
Insulin removal by dialysis has been less thor-
oughly studied; while its dialysance is likely to be
low in view of its mol wt (6,000 daltons), if the
transport gradient is very large then insulin can cross
conventional dialysis membranes, although poorly
[28]. The observed fall in insulin levels seen after
conventional glucose-free hemodialysis has been ex-
plained as being a normalization of metabolic clear-
ance rates and increase in fractional catabolic rates
of insulin induced by removal of "toxic" substances
by dialysis [29]. It is possible to explain the signifi-
cant fall in insulin levels after charcoal hemoperfu-
sion alone on this mechanism or on removal of insu-
lin by adsorption on charcoal. It has been shown that
insulin can be adsorbed from solution onto activated
charcoal in vitro [15]. Uncoated charcoal can re-
move molecules with a mol wt up to about 12,700
daltons. Coated charcoal also possesses this ability
but with lesser affinity [301. In the dialyzed or
combined-treatment patients, although significant
changes in insulin concentrations were observed dur-
ing the treatment periods, there was no overall effect
on insulin levels, possibly due to the stimulation of
insulin response to glucose administration via dialy-
sate (206mg of glucose/100 ml). By contrast, adsorp-
tion of human growth hormone (HGH) on charcoal is
unlikely since its mol wt is 21,500 daltons [31]. The
consistent reduction in HGH seen with all treatments
may be due to either glucose suppression of pituitary
HGH in the dialyzed and combined-treatment groups
and/or the postulated effects of heparin-induced re-
duction of HGH [32] through rises in free fatty acids.
The changes in amino acid concentrations with
hemodialysis or combined hemoperfusion/hemodial-
ysis in this study are consistent with the effects of
hemodialysis on removal of amino acids [33, 34].
Addition of hemoperfusion to hemodialysis reduced
the levels of alanine, cystine, glycine, threonine,
valine, and histidine, although hemoperfusion alone
resulted only in significant cystine reduction. The
latter observation may reflect a small reduction in
cystine synthesis or uptake of cystine preferentially
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by acrylic hydrogel-coated charcoal during hemoper-
fusion, although the latter would seem unlikely. Ad-
sorption of a substance to charcoal is dependent on
its molecular structure, and the rate-limiting step to
diffusion is the macroporous structure of carbon
[35]. Oules et al [19] have recently reported that in
uremic patients, charcoal hemoperfusion (using the
Adsorba 300 C system) removed phenylalanine, ty-
rosine, and arginine, and that serine, glycine, and
alanine were released from the charcoal column after
initial adsorption. The rise in serine concentration
that we have observed after hemoperfusion alone
may reflect serine-release from charcoal. In hepatic
coma, the aromatic amino acids, histidine, phenylal-
anine, and tyrosine are more readily removed with
little or no removal of serine [36, 37] or cystine [36]
by acrylic hydrogel-coated charcoal hemoperfusion.
Hemostatic changes occurring with hemoperfu-
sion have recently been reviewed [38]. The average
platelet loss occurring with hemoperfusion in poison-
ing or hepatic coma is of the order of 30%. Although
rises in SFP have been reported with charcoal hemo-
perfusion in hepatic coma [39] and previously with
hemodialysis [40], we observed no significant
changes in SFP with hemoperfusion alone and with
hemodialysis alone. Minor alterations in fibrinogen
concentrations observed in this study support the
conclusion that acrylic hydrogel-coated charcoal is
hemocompatible and contrasts with the substantial
changes in fibrinogen concentrations observed after
treatment with early uncoated charcoal hemoperfu-
sion devices [5, 61.
It is not yet possible to define the role of charcoal
hemoperfusion in uremia, but in terms of solute re-
moval it would seem desirable to increase the effi-
ciency of small solute removal and to combine hemo-
perfusion with hemodialyzer or ultrafiltration device
for fluid and electrolyte removal. Repetitive utiliza-
tion of the wide spectrum sorbent properties of acti-
vated charcoal in a hybrid hemoperfusion/hemodial-
ysis device is a likely future development for the
management of uremic patients.
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